Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| MDA2013-02-02 | CP-CTNet_CLO-MD Anderson | Effect of Aspirin on Biomarkers of Barrett’s Esophagus After Successful Eradication of Barrett’s Esophagus with Radiofrequency Ablation | Cancer Prevention and Control CIRB | Completed | |
| MDA2014-04-01 | CP-CTNet_CLO-MD Anderson | Alternative Dosing of Exemestane in Postmenopausal Women with Stage 0-II ER-Positive Breast Cancer: a Randomized Presurgical Trial | Cancer Prevention and Control CIRB | Completed | |
| MDA2014-04-02 | CP-CTNet_CLO-MD Anderson | VADIS Trial: Phase II trial of Nelipepimut-S Peptide Vaccine in Women with DCIS of the Breast | Cancer Prevention and Control CIRB | Completed | |
| MDA2016-07-02 | CP-CTNet_CLO-MD Anderson | A Randomized, Double-blind, Placebo-controlled Study of 4-hydroxytamoxifen Topical Gel in Women with Mammographically Dense Breast | Cancer Prevention and Control CIRB | Available to Open | |
| MDA2016-08-02 | CP-CTNet_CLO-MD Anderson | A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer | Cancer Prevention and Control CIRB | Completed | |
| MDA2017-09-03 | CP-CTNet_CLO-MD Anderson | Pilot Study of Denosumab in BRCA1/2 Mutation Carriers scheduled for Risk-reducing Salpingooophorectomy | Cancer Prevention and Control CIRB | Completed | |
| MDA21-06-01 | CP-CTNet_CLO-MD Anderson | A Phase Ib/II Clinical Trial of Nous-209 for Recurrent Neoantigen Immunogenicity and Cancer Immune Interception in Lynch Syndrome | Cancer Prevention and Control CIRB | Available to Open | |
| MM1MDS-A01 | Alliance | A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study | Adult CIRB - Late Phase Emphasis | Available to Open | |
| MM1OA-EA02 | ECOG-ACRIN | A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial | Adult CIRB - Late Phase Emphasis | Available to Open | |
| MM1YA-S01 | SWOG | A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by myeloMATCH; A myeloMATCH Clinical Trial | Adult CIRB - Late Phase Emphasis | Available to Open |